Idarubicin Accord 5 mg/5 ml Norge - norska - Statens legemiddelverk

idarubicin accord 5 mg/5 ml

accord healthcare b.v. - idarubicinhydroklorid - injeksjonsvæske, oppløsning - 5 mg/5 ml

Ondansetron Kalceks 2 mg/ ml Norge - norska - Statens legemiddelverk

ondansetron kalceks 2 mg/ ml

as kalceks - ondansetronhydrokloriddihydrat - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml

Lapatinib Newbury 250 mg Norge - norska - Statens legemiddelverk

lapatinib newbury 250 mg

newbury pharmaceuticals ab - lapatinib ditosylatmonohydrat - tablett, filmdrasjert - 250 mg

Breyanzi Europeiska unionen - norska - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiske midler - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Lunsumio Europeiska unionen - norska - EMA (European Medicines Agency)

lunsumio

roche registration gmbh - mosunetuzumab - lymfom, follikulært - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Tecvayli Europeiska unionen - norska - EMA (European Medicines Agency)

tecvayli

janssen-cilag international n.v. - teclistamab - multippelt myelom - antineoplastiske midler - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Columvi Europeiska unionen - norska - EMA (European Medicines Agency)

columvi

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Talvey Europeiska unionen - norska - EMA (European Medicines Agency)

talvey

janssen-cilag international n.v. - talquetamab - multippelt myelom - antineoplastiske midler - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Tepkinly Europeiska unionen - norska - EMA (European Medicines Agency)

tepkinly

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Lynparza 100 mg Norge - norska - Statens legemiddelverk

lynparza 100 mg

abacus medicine a/s - olaparib - tablett, filmdrasjert - 100 mg